Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Rare Disease Roundtable: How Rare Is Too Rare?

Apr 01 2019

• By Emily Hayes

Roundtabel participants seatedat table with Emily Hayes

Related Content

When The Trial Site Is A Living Room: Pharma Explores Virtual Research Options

Jan 21 2019

Orphan Drugs Compose Majority Of Novel US Approvals For First Time Ever In 2018

Jan 03 2019

Ultragenyx Gets Second Drug Approval; Crysvita With Kyowa Hakko Kirin

Apr 18 2018

Mereo Halts Plans For US Listing

Apr 27 2018

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

May 25 2018

J.P. Morgan Roundtable: Financing Challenges, And Opportunities, For Complex Therapies

Feb 07 2019

Rare Disease Roundtable: Dealing With Pricing Pressure

Apr 03 2019

Novartis Goes Big On Gene Therapy With $8.7bn AveXis Acquisition

Apr 09 2018

The Next Roivant Or Fortress? BridgeBio Raises $135m To Spin Out New Companies

Sep 18 2017

Related Companies

Novartis AG

Amarin Corp plc

Mirum Pharmaceuticals, Inc.

BridgeBio Pharma, Inc.

Pliant Therapeutics, Inc.

Ultragenyx Pharmaceutical Inc.

Additional Topics

Rare Diseases Clinical Trials StartUps and SMEs Research & Development BioPharmaceutical

More from Rare Diseases

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window